Literature DB >> 15303008

Pseudo-lysosomal storage disease caused by EMLA cream.

H Vallance1, T Chaba, L Clarke, G Taylor.   

Abstract

Prilocaine-lidocaine emulsion (EMLA cream) is a topical anaesthetic commonly used prior to diagnostic and therapeutic procedures. While undergoing clinical investigation for the suspicion of a metabolic disorder, a series of children underwent skin biopsy with EMLA cream pretreatment. In each case, the pathologist identified ultrastructural features consistent with a lysosomal storage disorder, yet the clinical features were not consistent with the pathological findings. Ultrastructural artefact was suspected, resulting from the use of the EMLA cream. All patients underwent repeat skin biopsy without EMLA cream. Biopsies were reviewed by two pathologists blinded to the previous biopsy findings. Electron microscopy repeated without the use of EMLA cream was normal. It is concluded that the use of EMLA cream causes ultrastructural artefact and should be avoided prior to skin biopsy for electron microscopy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15303008     DOI: 10.1023/B:BOLI.0000037352.98317.5a

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  2 in total

1.  Prilocaine/lidocaine patch as a local premedication for skin biopsy in children.

Authors:  F B de Waard-van der Spek; P G Mulder; A P Oranje
Journal:  J Am Acad Dermatol       Date:  1997-09       Impact factor: 11.527

2.  Histopathology of an adverse reaction to a eutectic mixture of the local anesthetics lidocaine and prilocaine.

Authors:  D M Hoss; E G Gross; J M Grant-Kels
Journal:  J Cutan Pathol       Date:  1999-02       Impact factor: 1.587

  2 in total
  1 in total

1.  Pharmacological modulators of autophagy activate a parallel noncanonical pathway driving unconventional LC3 lipidation.

Authors:  Elise Jacquin; Stéphanie Leclerc-Mercier; Celine Judon; Emmanuelle Blanchard; Sylvie Fraitag; Oliver Florey
Journal:  Autophagy       Date:  2017-02-15       Impact factor: 16.016

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.